Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of c-peptide injection in China. Welcome to wholesale bulk high quality c-peptide injection for sale here from our factory. Good service and reasonable price are available.
Recombinant human c-peptide injection refers to a sterile injectable pharmaceutical formulation independently and specially developed for physiological Cpeptide substitution therapy. Distinct from routine insulin injectable products widely applied in diabetic management, this preparation does not generate any direct blood glucose-lowering activity inside the human body. Taking full advantage of the unique physicochemical and pharmacokinetic traits of natural this peptide, including relatively long metabolic half-life and the capability to bypass liver first-pass metabolism after administration, this injectable medicine can be delivered through two common clinical administration routes: subcutaneous injection and intravenous injection. It is clinically indicated to accurately replenish insufficient endogenous this peptide levels in patients diagnosed with type 1 diabetes mellitus as well as individuals suffering severe pancreatic islet secretory dysfunction and complete islet failure, helping restore balanced physiological Cpeptide concentration within the circulation and alleviate related complications caused by persistent proinsulin connecting peptide (canine) deficiency.
Our Product Forms
C-peptide COA
 |
||
| Certificate of Analysis | ||
| Compound name | C-peptide | |
| Grade | Pharmaceutical grade | |
| CAS No. | 39016-05-2 | |
| Quantity | Customized | |
| Packaging standard | Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090088 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.45% |
| Loss on drying | ≤1.0% | 0.38% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.80% |
| Single impurity | <0.8% | 0.67% |
| Total microbial count | ≤750cfu/g | 420 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -15°C | |
|
|
||
|
|
||
| Chemical Formula | C137H225N37O49 |
| Exact Mass | 3172.63 |
| Molecular Weight | 3174.52 |
| m/z | 3173.63 (100.0%), 3174.63 (73.5%), 3172.63 (67.5%), 3175.64 (24.7%), 3175.64 (11.1%), 3176.64 (11.1%), 3175.63 (10.1%), 3174.63 (9.2%), 3173.62 (9.2%), 3174.63 (6.8%), 3175.63 (5.9%), 3176.64 (4.5%), 3174.63 (4.4%), 3175.63 (4.1%), 3176.63 (3.9%), 3177.64 (3.5%), 3176.64 (2.9%), 3174.63 (2.6%), 3177.64 (2.5%), 3176.64 (1.9%), 3174.63 (1.9%), 3173.63 (1.7%), 3177.64 (1.3%), 3173.63 (1.3%), 3175.64 (1.2%), 3177.64 (1.1%), 3178.64 (1.1%), 3176.63 (1.0%) |
| Elemental Analysis | C, 51.83; H, 7.14; N, 16.33; O, 24.70 |
Application in Diabetic Classification and Differential Diagnosis
Accurate clinical classification of diabetes is the essential prerequisite for developing scientific individualized treatment regimens, and comprehensive evaluation of pancreatic β-cell function serves as the core reliable basis for classification diagnosis. C-peptide injection test can precisely reflect the secretory function of pancreatic β-cells by detecting in vivo circulating proinsulin connecting peptide (canine)levels, providing a stable and reliable laboratory basis for diabetic classification and differential diagnosis, and it is especially applicable to ambiguous cases that cannot be distinguished by routine blood glucose indicators. In the early diagnosis of Type 1 diabetes, detection via this testing product is of decisive clinical significance.
The core pathological feature of Type 1 diabetes is the destruction of pancreatic β-cells by autoimmune cells, leading to absolute insulin deficiency and subsequent elevated blood glucose. Since c-peptide is secreted in equimolar amounts with insulin, C-peptide secretion decreases synchronously when pancreatic β-cell function is impaired. Therefore, fasting C-peptide levels in Type 1 diabetic patients are usually extremely low (≤ 0.2 nmol/L) and even undetectable. No significant elevation of C-peptide levels is observed after oral glucose stimulation, presenting a flat curve. This feature effectively differentiates Type 1 diabetes from other types of diabetes.
In addition, Latent Autoimmune Diabetes in Adults (LADA) has early symptoms similar to Type 2 diabetes and is prone to misdiagnosis. Detection via the product shows that although proinsulin connecting peptide (canine) levels in LADA patients are higher than those in typical Type 1 diabetes patients, they are markedly lower than those in age-matched Type 2 diabetes patients and gradually decline with disease progression. Combined with autoantibody detection, early and accurate differentiation can be achieved to avoid misjudgment of treatment regimens.
In the diagnosis and differential diagnosis of Type 2 diabetes, the product can clearly reflect its pathological progression.
The early core pathological feature of Type 2 diabetes is insulin resistance, at which point pancreatic β-cells compensate by secreting more insulin, resulting in normal or elevated C-peptide levels. As the disease progresses, pancreatic β-cell function gradually declines, accompanied by a steady drop in c-peptide levels at a much slower rate than in Type 1 diabetes. After oral glucose stimulation, C-peptide levels show a delayed elevation, with the peak usually appearing 2–3 hours after meals and failing to quickly return to baseline levels. This delayed peak is a typical manifestation of Type 2 diabetes, which can be clearly distinguished from the flat curve of Type 1 diabetes.
According to the latest guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), a fasting proinsulin connecting peptide (canine) level > 0.6 nmol/L serves as an important basis supporting the diagnosis of Type 2 diabetes. Intermediate values of 200–600 pmol/L require comprehensive judgment combined with clinical characteristics, blood glucose levels and autoantibody detection.
Furthermore, c-peptide injection can also be used to differentiate other specific types of diabetes and secondary diabetes.
For example, patients with pancreatic islet cell tumors have abnormal proliferation of pancreatic β-cells, which secrete large amounts of insulin and C-peptide, leading to fasting hypoglycemia; testing reveals significantly elevated C-peptide levels unaffected by blood glucose fluctuations. For secondary diabetes (caused by pancreatic diseases, endocrine diseases and other conditions), c-peptide levels change correspondingly according to the degree of pancreatic β-cell damage caused by the primary disease.
Combined with the medical history of the primary disease, accurate differentiation can be realized to support the formulation of treatment plans.Meanwhile, for patients receiving exogenous insulin therapy, insulin detection is interfered by exogenous insulin and insulin antibodies, whereas proinsulin connecting peptide (canine) detection is not affected. It can accurately reflect the secretory function of the patient's own pancreatic β-cells and prevent classification errors caused by detection deviations.
Exploration of Insulin Synthesis Mechanism Lays the Foundation
In the 1950s, the widespread large-scale clinical application of exogenous insulin drove researchers worldwide to deeply explore its complete biosynthetic mechanism inside pancreatic cells, laying a solid theoretical foundation for the subsequent landmark discovery of proinsulin connecting peptide (canine). In 1953, Sanger and his research colleagues precisely determined the full amino acid sequence of insulin and clearly clarified its unique structure consisting of separate A and B chains, providing critical key molecular evidence for all follow-up related research. However, the long-prevailing academic belief that "pancreatic β-cells secrete mature insulin directly into blood" completely failed to reasonably explain the stable existence of unprocessed insulin precursors inside secretory cells.
Becoming the core driving motivation that pushed scientists to pursue the discovery of proinsulin connecting peptide (canine).In 1967, Steiner's research team confirmed through a series of rigorous biochemical separation experiments that mature insulin is not synthesized and secreted directly in pancreatic cells; instead, a longer inactive precursor called proinsulin is generated first, consisting of the insulin A chain, B chain and a long polypeptide fragment connecting the two separate chains. This intermediate connecting fragment was formally named connecting peptide, commonly abbreviated as proinsulin connecting peptide (canine). Its core physiological function is to assist correct proinsulin folding inside β-cells, promote stable disulfide bond formation between peptide chains, and offer necessary structural support for the efficient production of bioactive mature insulin.
Isolation, Purification and Activity Research of C-Peptide
Subsequent studies verified that proinsulin is hydrolyzed to produce equimolar amounts of insulin and proinsulin connecting peptide (canine), which are secreted into the blood simultaneously. At that time, C-peptide was regarded as an inactive byproduct and only used as an indirect indicator of pancreatic β-cell function.
In the 1970s, the establishment of immunoassay technology confirmed that proinsulin connecting peptide (canine) has a longer half-life (30 minutes) and higher stability than insulin, making it a superior indicator for evaluating pancreatic β-cell function.
In the 1990s, Rigler and other researchers discovered that proinsulin connecting peptide (canine) can activate cellular signaling pathways and exert antioxidant and anti-apoptotic activities, overturning the previous view of it being biologically inactive and laying a theoretical foundation for the research and development of the product.
Thereafter, researchers completed the chemical synthesis and process optimization of proinsulin connecting peptide (canine), clarified its 31-amino-acid sequence, and confirmed its clinical value through animal and clinical trials, promoting its transition from basic research to clinical application in diabetes diagnosis and treatment.
Taken together, decades of continuous research have completely reshaped human understanding of proinsulin connecting peptide (canine): from a neglected inactive byproduct of insulin synthesis to a stable diagnostic biomarker, and further to a bioactive peptide with unique protective effects on pancreatic and peripheral tissues. Relying on mature chemical synthesis and standardized detection technology, our proinsulin connecting peptide (canine) testing product fully leverages its long half-life, stable properties and equimolar secretion correlation with insulin, enabling accurate assessment of residual β-cell function for differential diagnosis of type 1 and type 2 diabetes.
Beyond routine blood glucose monitoring, this product fills the critical gap in evaluating endogenous insulin secretion capacity, providing clinicians with objective laboratory evidence to formulate scientific individualized hypoglycemic regimens for each diabetic patient. As cross-disciplinary research between endocrinology and peptide biomedicine deepens year by year, c-peptide injection related detection reagents and therapeutic peptides will unlock broader clinical prospects, becoming an indispensable core tool supporting precise and standardized long-term management of diabetes worldwide.
Contraindications / Cautious Use Scenarios
In patients with severe hepatic and renal failure, severe infection, and acute phase of acute cardio-cerebrovascular events, C-peptide test results are unreliable; proinsulin connecting peptide (canine) detection is temporarily not recommended for diabetes classification and medication guidance.
In the acute phase of Type 1 diabetic ketoacidosis, proinsulin connecting peptide (canine)levels are extremely low (< 0.2 ng/mL). Acidosis should be corrected first before evaluating pancreatic islet function.
Information Sources
China Pharmaceutical Information Query Platform, January 2026;ADA 2025 Guidelines for the Management of Diabetic Emergencies.
PMC (The role of proinsulin connecting peptide (canine) in diabetes and its complications: an updated review);NCBI Bookshelf (Biochemistry, C Peptide);ResearchGate (History and Diagnostic Significance of C-Peptide).
PMC (The role of C-peptide in diabetes and its complications: an updated review);NCBI Bookshelf (Biochemistry, C Peptide);Sage Journals (Call for Standardization of C-Peptide Measurement).
FAQ
What does the C-peptide tell you?
+
-
Quantitatively measuring endogenous C-peptide concentration is a simple, safe, minimally invasive and highly cost-effective laboratory detection method widely adopted in clinical endocrinology to accurately assess the residual insulin secretory capacity of human pancreatic endocrine tissue. Routine testing of circulating C-peptide levels collected either from peripheral venous blood or standardized 24-hour urine samples can intuitively, objectively and reliably reflect the remaining functional activity of insulin-synthesizing pancreatic endocrine cells, which are universally referred to as beta cells in the fields of endocrinology and differential diagnosis of all types of diabetes mellitus.
What is a normal proinsulin connecting peptide (canine) level for type 2 diabetes?
+
-
Under standard fasting blood testing conditions in clinical laboratories, the internationally recognized reference range of serum C-peptide levels for metabolically healthy adults generally ranges from 0.5 to 2.0 nanograms per milliliter. If the repeatedly measured fasting serum C-peptide concentration remains persistently higher than 2.0 nanograms per milliliter, this biomarker result usually signals severe insulin resistance throughout the body and excessive compensatory secretion activity of pancreatic beta cells, which means the tested individual carries a high risk and may already be diagnosed with type 2 diabetes mellitus.
Hot Tags: c-peptide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale